Table 4.
Percent of patients surviving until years 3, 5, and 9 and median survival for patients with distant recurrence, triple-negative, and HER2-positive stage II-III breast cancer, propensity weighted based on receipt of surveillance within 3 years of diagnosis
| Mode of recurrence detection for each tumor subtype group | No. | Surviving 3 years, % | Surviving 5 years, % | Surviving 9 years, % | Survival in monthsa, median (95% CI) |
|---|---|---|---|---|---|
| ER+ or PR+, HER2- | |||||
| Asymptomatic imaging | 141 | 73.7 | 39.3 | 11.1 | 50.2 (43.6 to 58.8) |
| Signs and/or symptoms | 469 | 77.4 | 45.3 | 10.5 | 58.2 (55.2 to 61.1) |
| ER- and PR-, HER2- | |||||
| Asymptomatic imaging | 84 | 54.2 | 24.6 | 8.9 | 39.0 (33.1 to 44.8) |
| Signs and/or symptoms | 254 | 45.3 | 16.2 | 6.5 | 33.7 (30.2 to 37.7) |
| HER2+ | |||||
| Asymptomatic imaging | 59 | 85.1 | 52.5 | 13.8 | 63.9 (49.4 to 72.1) |
| Signs and/or symptoms | 213 | 68.0 | 38.1 | 13.4 | 51.4 (44.2 to 58.2) |
a
Days converted to months assuming 30 days in each month. ER = estrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2.